Clinical Trial of ATYR1923 for Treating Pulmonary Sarcoidosis

by | Jan 26, 2021

  Sanjay Shukla, MD, the president and CEO of aTyr Pharma, discusses the development of its ATYR1923 therapy for pulmonary sarcoidosis, including clinical trials currently under way. Pulmonary sarcoidosis is an interstitial lung disease characterized by the...

Overview of Pulmonary Sarcoidosis

by | Jan 23, 2021

  Sanjay Shukla, MD, the president and CEO of aTyr Pharma, provides an overview of pulmonary sarcoidosis, including diagnostic indicators. Pulmonary sarcoidosis is an inflammatory disease characterized by the development and growth of tiny lumps of cells called...

Horizon Therapeutics’ Personal Approach to Rare Diseases

by | Jan 22, 2021

  Elizabeth Thompson, PhD at Horizon Therapeutics explains why rare diseases — like thyroid eye disease (TED) — are at the heart of the company’s mission. TED is a rare autoimmune disease causing permanent facial disfigurement severely affecting patients’ quality...

Supporting Patient-Advocacy Groups During the Covid Pandemic

by | Jan 21, 2021

  Stephanie Brown, the SVP of rare diseases at Ipsen Biopharmaceuticals, explains how the company has continued its commitment to rare disease organizations — including those dedicated to acromegaly and  fibrodysplasia ossificans progressiva (FOP) — during the...